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1098 The Journal of Thoracic and CardObjective: Cytokine dysregulation contributes to the systemic inflammatory response
after cardiopulmonary bypass. Clearance of cytokine binding proteins may be important
in the resolution of inflammation. Our aim was to determine whether the cytokine
binding protein 2-macroglobulin and its soluble receptor were upregulated in endotra-
cheal aspirates from infants and children undergoing cardiopulmonary bypass.
Methods: Seventy tracheal aspirates were collected before and after cardiopulmo-
nary bypass from 35 infants and children undergoing surgical correction of con-
genital heart defects. 2-Macroglobulin and the soluble 2-macroglobulin receptor
were identified by Western blot. With the use of multi-analyte cytokine profiling,
pro-inflammatory and anti-inflammatory cytokines were quantified, normalized to
total protein, and expressed as ratios. Paired t tests and Wilcoxon signed-rank tests
were performed between prebypass and postbypass samples. Correlations were
examined among 2-macroglobulin, soluble 2-macroglobulin receptor, cytokine
ratios, and the clinical variables of cardiopulmonary bypass, aortic crossclamp, and
circulatory arrest times.
Results: 2-Macroglobulin increased by 50% (mean densitometry increase 82,683
 184,594, P  .012), and soluble 2-macroglobulin receptor increased by 17%
(mean densitometry increase 506,148 687,037, P .0001) after cardiopulmonary
bypass. The ratio of interleukin-8/interleukin-4 increased by 136% (P .0001), and
interleukin-8/interleukin-10 increased by 102% (P  .001). The increase in soluble
2-macroglobulin receptor was positively correlated with the ratios of interleukin-
8/interleukin-4 and interleukin-8/interleukin-10. There were no statistically significant
positive correlations between the increase in 2-macroglobulin or soluble 2-macro-
globulin receptor and measured clinical variables.
Conclusions: We report for the first time the upregulation of 2-macroglobulin and
soluble 2-macroglobulin receptor in tracheal aspirates after cardiopulmonary by-
pass in infants and children. Soluble 2-macroglobulin receptor correlates with
increased 2-macroglobulin and a disproportionate increase in pro-inflammatory to
anti-inflammatory cytokine ratios.
Cardiopulmonary bypass (CPB) contributes to a systemic inflammatoryresponse by activation of cellular and humoral cascades. Inflammationafter CPB is similar to sepsis. It involves activation of immunocompe-
tent cells, complement and coagulation, endothelial cell dysfunction, proteinase/
antiproteinase imbalance, and increased cytokine production, and may lead to
multiorgan dysfunction.1-3 In particular, lung dysfunction after CPB can have
detrimental effects on oxygen delivery and require ventilator management that
may worsen cardiac output through unfavorable cardiorespiratory interactions.
The progression to severe lung disease is believed to occur when regulatory
mechanisms fail and inflammation becomes self-propagating.4 This auto-
amplification may be the result of increased production or decreased clearance of
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Dcytokines. Ultimately, the balance of pro-inflammatory and
anti-inflammatory factors influences subsequent lung injury.
In addition to its role as a proteinase inhibitor, 2-
macroglobulin (2M) also functions as a cytokine binding
protein.5,6 At sites of inflammation, 2M undergoes a con-
formational change to a receptor-recognized form, 2M*.
We have shown that 2M* demonstrates increased binding
to many cytokines and growth factors.5,7 In vivo, 2M* is
increased in endotracheal aspirates (ETAs) from infants
with lung disease,8,9 and 2M*-cytokine complexes have
been identified in bronchoalveolar lavage (BAL) from
adults with acute respiratory distress syndrome.10,11 The
increased 2M may result from increased production/se-
questration or decreased clearance. In general, cytokines
and growth factors complexed with 2M* retain their bio-
logic activity. However, 2M*-cytokine complexes are rap-
idly cleared when bound to the 2M cell surface receptor
Figure 1. Transition of 2-macroglobulin (2M) (blue
proteinases (red circles) and binding of cytokines (gre
receptor (2MR) at the cell surface with subsequent in
the 2MR. The soluble 2MR (S2MR) results from
competitively inhibit clearance of 2M-cytokine comp(2MR).7
The Journal of Thoracic2MR is a classic scavenger receptor found on many cell
types including hepatocytes, monocytes, and macrophages.
Recent studies have identified a soluble form of 2MR
(S2MR) with intact receptor binding that circulates in
human plasma.12,13 An S2MR that maintains its ligand-
binding properties should act as a competitive inhibitor for
the cellular form of the receptor. Soluble 2MR may inhibit
the cellular internalization of 2M*-cytokine complexes
(Figure 1).
We evaluated the 2M*-cytokine regulatory axis, and
our study for the first time demonstrates the relative increase
of S2MR in ETAs from infants and children after the
inflammatory insult of CPB. The increase in S2MR corre-
lated with increased levels of the ratio of pro-inflammatory
to anti-inflammatory cytokines. Increased levels of S2MR
may prolong the course of inflammation within the lung
after CPB by increasing the half-life of 2M*-cytokine
ecule) to receptor-recognized form with exposure to
rcles). 2M-cytokine complexes may bind to the 2M
lization and degradation or bind to the soluble form of
vage of the 2MR near the cell surface and may
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Monoclonal antibodies directed against the  chain of human
2MR were purchased from Pharmingen (San Diego, Calif). Poly-
clonal antibodies directed against 2M were purchased from
Sigma (St Louis, Mo). Reagents for sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, polyvinylidene difluoride
membranes, and transfer reagents were purchased from Bio-Rad
(Richmond, Calif). An enhanced chemifluorescent immunoblot-
ting kit was purchased from Amersham (Buckinghamshire, United
Kingdom). Complete protease inhibitors were purchased from
TABLE 1. Patient demographics
Diagnosis Surgery Age
HLHS Norwood 2 d
HLHS Norwood 4 d
HLHS Norwood 6 d
HLHS Norwood 7 d
Mean
AVSD AV canal repair 1 mo
VSD VSD closure 2 mo
TOF 1° repair 3 mo
Mitral insufficiency MVR 3 mo
TOF 1° repair 3 mo
HLHS s/p Norwood Glenn 4 mo
TGA Glenn 4 mo
Tricuspid atresia Glenn 4 mo
HLHS s/p Norwood Glenn 4 mo
DORV Glenn 5 mo
DORV Glenn 6 mo
TOF 1° repair 6 mo
AVSD AV canal repair 8 mo
HLHS Glenn 11 mo
Mean
ASD ASD closure 20 mo
HLHS Fontan 2 y
ASD ASD closure 2 y
TOF s/p repair Conduit change 2 y
HLHS Fontan 3 y
ASD, PAPVR ASD closure 3 y
PAPVR, ALCAPA, ASD ASD closure, CAG 3 y
ASD ASD closure 3 y
AV canal Fontan 5 y
TOF PVR, conduit 5 y
ASD ASD closure 6 y
Pulmonary atresia, PI PVR 6 y
Pulmonary stenosis PVR 7 y
ASD ASD closure 7 y
VSD VSD closure 8 y
RVOT obstruction Conduit 8 y
Ebstein TVR 10 y
Mean
CPB, Cardiopulmonary bypass; X-clamp, crossclamp; CA, circulatory arres
VSD, ventricular septal defect; TOF, tetralogy of Fallot; MVR, mitral valve
double-outlet right ventricle; ASD, atrial septal defect; PAPVR, partial anom
pulmonary artery; CAG, coronary artery graft; PVR, pulmonary valve repla
tricuspid valve replacement.Roche (Indianapolis, Ind).
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After parental informed consent and Duke University Institutional
Review Board approval were obtained, ETAs were collected from
children (aged 2 days to 10 years) undergoing corrective congen-
ital heart surgery requiring CPB. In each patient, ETAs were
collected after intubation but before CPB. During CPB the lungs
were not ventilated, but the patient’s endotracheal tube remained
attached to the ventilator with humidified fresh gas flow. After
inflation, a second sample was collected immediately before the
separation from CPB, before the institution of modified ultrafiltra-
Weight (kg) CPB (min) X-clamp (min) CA (min)
2.7 185 76 15
2.9 166 60 10
2.8 165 59 12
2.7 177 68 4
173 66
2.9 213 101
3.3 104 70
5.3 52 28
4.6 89 54
5.6 100 49
5 181
5.5 72
5.7 80 5
4.5 120 69
6.1 60
6.8 77
7.5 98 58
4.9 108 67
7.3 82 10
103 51
10.4 51 40
11 58
14 51 37
13 96
14.3 172 64 35
15.2 33 13
17.6 106 65
16.7 39
15.5 82
18.7 103
21.4 60 38
22.4 59
31 65
26.5 72 42
20 52 28
28.3 57
23 65 33
72 40
S, hypoplastic left heart syndrome; AVSD, atrioventricular septal defect;
cement; s/p, status post; TGA, transposition of the great arteries, DORV,
s pulmonary venous return; ALCAPA, anomalous left coronary artery from
nt; PI, pulmonary insufficiency; RVOT, right ventricular outflow tract; TVR,t; HLH
repla
alou
cemetion. Samples were obtained with a sterile endotracheal suction
y 2005
Williams et al Surgery for Congenital Heart Disease
CH
Dcatheter. If necessary, patients received 0.5 to 1 mL of normal
saline to assist aspiration of secretions.
Anesthesia and CPB were per institutional protocol. All pa-
tients aged less than 1 month received intravenous methylpred-
nisolone 10 mg/kg (q6 2) preoperatively in addition to 30 mg/kg
on pump prime. Children aged more than 1 month received meth-
ylprednisolone 10 mg/kg on pump prime.
Sample Processing
After sample collection, 2.5 mL of Complete protease inhibitor (di-
lution 1:1) was added to prevent protein degradation, and the sample
was placed on ice. Within 4 hours, samples were centrifuged at 1000
rpm for 8 minutes to remove cellular debris. Subsequently, samples
were centrifuged at 100,000g for 30 minutes to isolate soluble com-
ponents and stored at 80°C for further analysis.
Immunoblotting
Total protein analysis was performed with the BCA Protein Assay
Kit (Pierce, Rockford, Ill). Polyacrylamide gel electrophoresis was
performed at 150V for 3.5 hours per the manufacturer’s instruc-
tions. All gels were loaded with identical total protein for each
pre-CPB and post-CPB pair. Western blotting was performed for
2M and S2MR. After application of fluorescent dye, blots were
dried and digitized on the Storm 860 gel and blot imaging system
(Molecular Dynamics, Sunnyvale, Calif). Image densitometry was
performed with ImageQuant v5.2 (Molecular Dynamics, Sunnyvale,
Calif). Quantitative multi-analyte cytokine profiling was performed
on all samples per standard protocol with 50-L samples on the
Luminex 100 (LuminexCorp, Austin, Tex).
Statistical analysis was performed by Microsoft Excel 2002
(Redmond, Wash) and SAS (Cary, NC) and consisted of paired
hypothesis tests between pre-CPB and post-CPB samples within
each patient for image densitometry and cytokine ratios. Paired t
Figure 2. A, Western blot analysis probing 2M within 4 patients’
endotracheal aspirate (ETA) samples. The 180 kDa band is the
2M subunit, 4 of which make up the native molecule. Pre-CPB
(a) and post-CPB (b) time points. B, Western blot analysis probing
S2MR within 4 patients’ ETA samples. The 55 kDa band rep-
resents the surface-cleaved extracellular portion of the 85 kDa
 chain. Pre-CPB (a) and post-CPB (b) time points.tests were used for normally distributed data, and Wilcoxon
The Journal of Thoracicsigned-rank tests were used for non-normally distributed data.
Spearman correlations were examined between S2MR, 2M, and
cytokine ratios as well as the clinical variables of CPB, aortic
crossclamp, and circulatory arrest times.
Results
All measured variables except 2M were not normally dis-
tributed and required the Wilcoxon signed-rank test to de-
termine statistical significance and are expressed as mean
SD. Patient demographics are tabulated in Table 1. In our
patients, 17 of 35 (49%) were aged more than 1 year and 18
of 35 (51%) were aged less than 1 year. Of the patients aged
less than 1 year, 4 of 18 (22%) were aged less than 1 month.
The longest CPB and aortic crossclamp times were required
in this same subpopulation. In addition, they received hy-
pothermic circulatory arrest. Aprotinin was administered to
only 2 of 35 patients (6%).
Representative Western blots for 2M and S2MR are
shown in Figure 2, A and B, respectively. The relative
increases after CPB of the 2MR -chain image density and
2M image density for all patients was 17% (mean densi-
tometry increase 506,148  687,037, P  .0001) and 50%
(mean densitometry increase 82,683  184,594, P  .012),
respectively.
Total protein increased before CPB to after CPB from
346  420 to 507  563 g/mL (P  .009). The results of
the multi-analyte cytokine profiling are shown in Table 2.
Interleukin (IL)-2, tumor necrosis factor-, and granulocyte-
macrophage colony-stimulating factor were below the limits of
detection of the multi-analyte cytokine analysis. Cytokines
normalized to total protein are shown in Table 3. The pro-
inflammatory to anti-inflammatory ratios of IL-8/IL-10 and
IL-8/IL-4 were increased after bypass. Specifically, mean IL-
8/IL-10 increased from 13.1 to 26.5 (102%) (P  .001), and
IL-8/IL-4 increased from 0.83 to 1.96 (136%) (P  .0001).
The increase in S2MR was positively correlated with
the increase in 2M (Spearman coefficient R  0.52, P 
.01). The increase in S2MR was also positively correlated
TABLE 2. Cytokine analysis
Cytokine
Pre
(pg/mL)  SD
Post
(pg/mL)  SD P
INF- 1362 3242 1917 3401 .052
IL-1 21.6 30.9 15.1 10.5 .435
IL-8 97.3 182 205 316 .0045
IL-10 5.6 3.2 6.3 3.2 .14
IL-6 29.9 62.7 6.01 9.03 .0002
IL-12 14.2 52 41.8 134 .384
IL-4 112 100 86 34 .449
IL-8/IL-4 0.83 1.39 1.96 2.7 .0001
IL-8/IL-10 13.1 21.1 26.5 36.7 .001
IL, Interleukin; INF, interferon.with the ratios of IL-8/IL-4 (Spearman coefficient R 0.50,
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 .05). There were no statistically significant positive cor-
relations between the increase in S2MR or 2M and the
clinical variables of CPB, aortic crossclamp, and circulatory
arrest times.
Discussion
During CPB, serum 2M has been found to decrease, most
likely because of dilutional effects.14,15 However, a critical
component of the 2M-cytokine regulatory axis is the 2M
receptor, a scavenger receptor located on many cell types.16
This study for the first time describes the increase of
S2MR in ETA from infants and children after the inflam-
matory insult of CPB. The increase in S2MR had a positive
correlation with 2M and the proinflammatory to anti-
inflammatory ratios of IL-8/IL-4 and IL-8/IL-10. Previous
in vivo research identified the presence of a soluble form of
2MR circulating in human plasma that maintained its
ligand-binding properties and was increased in inflamma-
tory states.12,13 Further in vitro modeling suggested that the
release of S2MR was through cleavage of 2MR at a
membrane proximal region by a membrane-tethered metal-
loproteinase (Figure 1).13,17 In vitro treatment with a met-
alloproteinase inhibitor decreased the cleavage of 2MR,
thereby decreasing the S2MR available to compete with
the cellular 2MR. Thus, mechanisms that affect the clear-
ance of 2M*-cytokine complexes, such as receptor com-
petition, could play a role in the modulation of inflammation
after CPB.
Our goal has been to evaluate the inflammatory response
within the lung in hopes of understanding the more clini-
cally severe forms of acute lung injury and acute respiratory
distress syndrome.18 We chose CPB as a model of inflam-
mation because of its predictable onset. This is in contrast
with the poor predictability of lung disease secondary to
sepsis, in which clinical samples before the onset of inflam-
mation may be impossible to obtain. We confirmed inflam-
matory upregulation after CPB by measuring the ratios of
inflammatory mediators IL-8/IL-4 and IL-8/IL-10 from the
TABLE 3. Normalized cytokine analysis
Cytokine/TP
Pre
(pg/g)  SD
Post
(pg/g)  SD P
INF-/TP 2.96 6.2 3.84 5.6 .218
IL-1/TP 0.46 1.3 0.07 0.17 .0001
IL-8/TP 0.88 2.9 0.42 0.67 .43
IL-10/TP 0.10 0.21 0.027 0.03 .028
IL-6/TP 1.48 5.9 0.06 0.21 .0001
IL-12/TP 0.19 0.78 0.04 0.11 .70
IL-4/TP 4.35 17.2 0.43 0.64 .002
INF, Interferon; IL, interleukin; TP, total protein.lung and found them increased.
1102 The Journal of Thoracic and Cardiovascular Surgery ● MaSystemic inflammation is upregulated by CPB with ac-
tivation of plasma protein systems: contact, intrinsic and
extrinsic coagulation, fibrinolysis, and complement, as well
as cellular systems: platelets, endothelial cells, neutrophils,
monocytes, and lymphocytes.3 Despite a complex inflam-
matory response, the majority of patients are extubated early
after CPB with minimal ventilatory requirements. However,
in patients requiring prolonged mechanical ventilation, pos-
itive pressure can exacerbate the inflammatory response
because of overdistension of lung tissue.19 Thus, both the
inflammatory insult and supportive therapy may potentiate
lung injury. To date, studies have implemented novel ther-
apies directed at reducing inflammatory cytokines and the
associated potential for prolonged inflammation (eg, ste-
roids, modified ultrafiltration, complement inhibitors, and
proteinase inhibitors).20-23 Despite these efforts, the physi-
ologic response to CPB in infants and children can be
exaggerated and lead to organ dysfunction in the postoper-
ative period, clinically evidenced in the lung.24
Clinically, lung disease may become exaggerated with
dysfunction of cytokine-binding proteins.25 Found in abun-
dance at sites of inflammation, 2M* binds a host of pro-
inflammatory cytokines and growth factors, and we previ-
ously showed that in vitro binding to 2M* is specific.5
2M* is increased in ETA from intubated infants with lung
disease.8,9 Studies have measured 2M* levels from BAL
fluid in infants and adults and found increases in those
patients with inflammatory lung diseases.26,27 The increase
in 2M* in BAL fluid has been presumed secondary to
leakage from plasma after lung injury and localized produc-
tion by alveolar macrophages and fibroblasts.25 We found
2M increased in the inflammatory state associated with
CPB. Decreased clearance of 2M*-cytokine complexes
may contribute to the increase in 2M*.
ETA samples were obtained as representative of the
milieu of the alveolar compartment. To date, ETA samples
have been used to measure components within the alveolar
compartment of intubated neonates and infants.8,9,28 Dilu-
tional effects on S2MR measurements have been taken
into account by loading identical protein concentrations on
the gels for pre-CPB and post-CPB samples. By examina-
tion of the ratio of pro-inflammatory to anti-inflammatory
cytokines at any time point, the dilutional variability can
also be removed. Here, the data indicate a disproportionate
increase in pro-inflammatory to anti-inflammatory medi-
ators before to after CPB. Despite these attempts, it is
unclear how well tracheal aspirates can represent the acel-
lular components of the lower respiratory tract and how well
we can use these measurements to distinguish temporal
changes resulting from pathology or therapy.
Interpretation of our results requires careful consider-
ation. Although we understand that steroids may alter the
inflammatory response to CPB, our study was not designed
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Dto determine this effect. Because of the inherent variability
of patient demographics and the influence of varying
amounts of immunomodulators, our current sample size
does not provide the statistical power required to delineate
the contributions of these effectors. For example, in addition
to having the lowest temperatures, all of the neonates (n 
4) received 2 additional doses of methylprednisolone before
their surgery on CPB. The lack of a statistically significant
increase in S2MR in the neonatal subgroup may not be
solely attributable to the small sample size of 4. Recent
clinical data indicate that combined preoperative and intra-
operative steroids can reduce inflammatory mediator ex-
pression greater than intraoperative steroids alone.29 Thus,
we cannot rule out the potential contribution from the extra
doses of steroids in this subgroup.
We report for the first time the presence of S2MR in
ETAs from infants and children and the increase of S2MR
after the inflammatory insult of CPB. On the basis of our
findings, we hypothesize that therapy directed at decreasing
cleavage of 2MR, by inhibiting metalloproteinases, will
lead to increased 2MR-dependent cellular internalization
and degradation of 2M*-cytokine complexes. This hypoth-
esis supports therapy directed at reducing or inhibiting
metalloproteinases within the lung to reduce inflamma-
tion.30 Future studies will be directed toward understanding
the mechanisms of 2MR release and the effect of S2MR
on the clearance of 2M*-cytokine complexes in vitro.
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